← Browse by Condition
Medical Condition

metastatic malignant solid neoplasm

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for metastatic malignant solid neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — metastatic malignant solid neoplasm Clinical Trials

How many clinical trials are currently recruiting for metastatic malignant solid neoplasm?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for metastatic malignant solid neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for metastatic malignant solid neoplasm?
metastatic malignant solid neoplasm research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a metastatic malignant solid neoplasm clinical trial?
Eligibility criteria for metastatic malignant solid neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
Mayo Clinic 2 trials
National Cancer Institute (NCI) 2 trials
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT06911008 Phase 1
Recruiting
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Enrollment
42 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06015932
Recruiting
Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients
Enrollment
400 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06311214 Phase 2
Recruiting
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Enrollment
500 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT05111561 Phase 1
Recruiting
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
Enrollment
42 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT04771520 Phase 2
Recruiting
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Enrollment
50 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

refractory malignant solid neoplasm (2) unresectable malignant solid neoplasm (2) advanced malignant solid neoplasm (2) hematopoietic and lymphoid system neoplasm (1) malignant solid neoplasm (1) triple negative breast carcinoma (1) anatomic stage iv breast cancer ajcc v8 (1) clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8 (1) clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8 (1) clinical stage ivb gastroesophageal junction adenocarcinoma ajcc v8 (1) locally advanced malignant solid neoplasm (1) locally advanced melanoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology